These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35282043)

  • 41. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():883399. PubMed ID: 35847924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unusual breast metastasis of gastrointestinal stromal tumor: A case report and literature review.
    Filonenko D; Karnaukhov N; Kvetenadze G; Zhukova L
    World J Clin Oncol; 2023 Mar; 14(3):131-137. PubMed ID: 37009526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
    Brown JB; Pai RK; Burgess MA; Chennat J; Zureikat AH
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1424-1428. PubMed ID: 30545989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
    Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastrointestinal stromal tumours.
    Blay JY; Kang YK; Nishida T; von Mehren M
    Nat Rev Dis Primers; 2021 Mar; 7(1):22. PubMed ID: 33737510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
    Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
    Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib.
    Dalle Fratte C; Guardascione M; De Mattia E; Borsatti E; Boschetto R; Farruggio A; Canzonieri V; Romanato L; Borsatti R; Gagno S; Marangon E; Polano M; Buonadonna A; Toffoli G; Cecchin E
    Front Pharmacol; 2020; 11():36. PubMed ID: 32116712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
    Na YS; Ryu MH; Yoo C; Lee JK; Park JM; Lee CW; Lee SY; Shin YK; Ku JL; Ahn SM; Kang YK
    Oncotarget; 2017 Sep; 8(44):76712-76721. PubMed ID: 29100343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
    Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
    Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
    Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
    World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 58. [A Case of GIST of the Stomach with Long-Term Survival after Multidisciplinary Treatment, Including Four Surgical Resections of Liver Metastases].
    Kitakaze M; Hirao M; Miyamoto A; Hamakawa T; Yamamoto K; Nishikawa K; Maeda S; Uemura M; Miyake M; Hama N; Miyazaki M; Ikeda M; Nakamori S; Kiyokawa H; Mano M; Sekimoto M
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2237-2239. PubMed ID: 28133281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
    Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.